Acelyrin, Inc. is making strides in its clinical trials, particularly with lonigutamab ('loni') for Thyroid Eye Disease (TED), leading to a 'Buy' rating from TD Cowen analyst Tyler Van Buren. The company's strategic focus and advancements in clinical development are key factors driving this positive assessment.
Lonigutamab's Clinical Progress
Acelyrin has successfully completed the first three cohorts of its Phase II study for lonigutamab in TED, with the fourth cohort currently underway. This progress indicates a robust pipeline moving towards Phase III trials. Key data and design details for the Phase III trials are expected to be revealed soon.
The alignment with the FDA on the Phase III trial design and dosing strategy underscores the company’s preparedness for the next phase of development. The use of MRI assessments and the potential for a faster patient response with a higher loading dose in Cohort 4 further strengthen the case for a positive outcome.
Strategic Advancements and Potential Superiority
Van Buren's 'Buy' rating is also influenced by the anticipated superior results of lonigutamab compared to existing treatments like Humira. These strategic advancements and the potential for improved patient outcomes contribute to the positive outlook for Acelyrin.
Acelyrin's Broader Pipeline
Acelyrin, Inc. is a clinical biopharmaceutical company focused on developing and commercializing transformative medicines. Their lead product candidate, izokibep, is in Phase 3 clinical trials for Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, and in Phase 2 trials for Axial Spondyloarthritis. Additionally, they are developing SLRN-517, a monoclonal antibody targeting c-KIT, currently in preclinical stages for chronic urticaria.
